BlackJack3D Gossamer Bio (NASDAQ:GOSS) is a clinical-stage biopharmaceutical company with a pipeline of one drug: Seralutinib. Seralutinib is focused on treating pulmonary arterial hypertension ("PAH") and pulmonary hypertension with interstitial lung disease ("PH-ILD"). The company has a history of disappointing investors, typical in biotech, as 90% of drugs fail clinical trials. This is what Gossamer's pipeline looked like in 2020: Harrow's Ophthalmic Pharmaceutical Brands ILEVRO. IOPIDINE 1% OPIDINE 0.5 ...

Gossamer Bio (GOSS) came out with quarterly earnings of $0.22 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to loss of $0.45 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -4.35%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.19 per share when it actually produced a loss of $0.19, delivering no surprise. Over the last four quarters, the company ...

Loading... In May, Gossamer Bio and Italy-based Chiesi Farmaceutici S.p.A entered a global collaboration and license agreement to develop and commercialize seralutinib. The analyst adds that Gossamer has strategically positioned seralutinib to enter large, underserved markets such as Japan. "We see shares trading below cash as creating an attractive entry point at current levels." Gossamer Bio is focused on developing and commercializing seralutinib for pulmonary arterial hypertension. It stands out with it ...

The company is not profitable yet but is guiding to be profitable in 2024. And revenue is increasing at an impressive pace. The stock doesn't get much analyst attention, but the four analysts that have issued a rating give MVST a consensus price target of $4.50, an 857% gain from its closing price on June 12, 2024. Source: PopTika / Shutterstock.com But all it takes is one. And that's also the number of candidates in Gossamer Bio's pipeline. The company has a candidate, Seralutinib (GB002), in a Phase 3 cli ...

Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update SAN DIEGO—(BUSINESS WIRE)— May 7, 2024 — Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the first quarter ended March 31, 2024 and provided a busine ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q _________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________to_________. Commission File Number: 001-38796 GOSSAMER BIO, INC. (Exact name of Registrant as specified in its charter) ...

Summary of Gossamer Bio (GOSS) Conference Call Company and Industry Overview - **Company**: Gossamer Bio (GOSS) - **Industry**: Pulmonary Hypertension Drug Development Key Points and Arguments 1. **Collaboration with Chiesi Group**: Gossamer announced a transformative collaboration with Chiesi Group, which is expected to enhance the development and commercialization of saralutinib for pulmonary hypertension (PH) [4][5][6] 2. **Financial Impact**: The collaboration provides Gossamer with $160 million in cash for clinical development reimbursement, potentially leading to over $600 million in total commitments from Chiesi for the development and commercialization of saralutinib [5][8][9] 3. **Accelerated Development Timeline**: The partnership allows Gossamer to initiate a Phase III clinical trial for pulmonary hypertension associated with interstitial lung disease (PHILD) much sooner than previously planned, potentially four to five years earlier [6][11][14] 4. **Market Opportunity**: PHILD is identified as a significant market opportunity with only one approved therapy in the U.S. and none globally, indicating a high unmet medical need [6][10][15] 5. **Regulatory Strategy**: Gossamer plans to engage with regulatory authorities to finalize the Phase III study design for PHILD, leveraging Chiesi's experience with global regulatory processes [45][46][56] 6. **Clinical Trial Design**: The ongoing PROCERA study for PAH is progressing well, with expectations for top-line results in Q4 2025. The study involves 175 patients per arm and focuses on the change in six-minute walk distance as a primary endpoint [17][18][19] 7. **Patient Population Characteristics**: The PHILD patient population is expected to be more severely impaired than typical PAH patients, which may enhance the observed treatment effects in clinical trials [21][73][74] 8. **Safety Profile**: Gossamer anticipates a favorable safety profile for saralutinib based on previous studies, which is crucial for its acceptance in the market [75] Additional Important Information 1. **Chiesi's Background**: Chiesi is a global biopharmaceutical group with extensive experience in respiratory and rare diseases, making it a suitable partner for Gossamer [11][12] 2. **Market Dynamics**: The introduction of new therapies like saralutinib is critical as existing treatments for PAH have limitations, and there is a growing need for alternative mechanisms of action [9][10][94] 3. **Regulatory Alignment**: Gossamer has achieved regulatory alignment with both the FDA and EMA for its ongoing studies, which is essential for the success of its clinical programs [56] 4. **Future Development Plans**: Gossamer retains strategic control over U.S. commercialization and global development, ensuring that it can guide the direction of its product pipeline effectively [90][91] This summary encapsulates the key discussions and insights from the Gossamer Bio conference call, highlighting the strategic collaboration with Chiesi, the financial implications, and the potential market opportunities in the pulmonary hypertension space.

Strategic collaboration to leverage Chiesi's legacy of respiratory leadership and Gossamer Bio's development expertise in pulmonary hypertension. Gossamer to receive $160 million development reimbursement payment and eligible to receive up to $146 million in regulatory and $180 million in sales milestones. 50/50 commercial profit split in US and global development cost sharing arrangement. Chiesi obtains exclusive ex-US development, manufacturing, and commercial rights, with Gossamer to receive mid-to-high ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 __________________________________________________________________________________ FORM 10-K __________________________________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38796 _____ ...

Exhibit 99.1 Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update - First PAH Patient Dosed in Ongoing Registrational Phase 3 PROSERA Study - - Inclusion of Japan in Phase 3 PROSERA Study Following CTN Acceptance by PMDA - - Cash, cash equivalents and marketable securities totaled $296 million at year-end 2023 - SAN DIEGO — (BUSINESS WIRE) — March 5, 2024 — Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the developm ...